Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has been assigned a $9.00 price objective by equities researchers at HC Wainwright in a report issued on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 94.38% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Rodman & Renshaw initiated coverage on shares of Pieris Pharmaceuticals in a research report on Tuesday, May 30th. They set a “buy” rating and a $9.00 target price for the company. Finally, TheStreet raised shares of Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Wednesday, May 3rd. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $8.25.

Pieris Pharmaceuticals (PIRS) opened at 4.63 on Friday. The company’s 50-day moving average is $5.35 and its 200 day moving average is $3.55. The company’s market cap is $199.40 million. Pieris Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $6.20.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by $0.35. The firm had revenue of $1.34 million for the quarter, compared to analyst estimates of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 459.73% and a negative return on equity of 123.78%. On average, equities analysts predict that Pieris Pharmaceuticals will post ($0.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/hc-wainwright-analysts-give-pieris-pharmaceuticals-inc-pirs-a-9-00-price-target.html.

Hedge funds have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $132,000. Creative Planning increased its stake in Pieris Pharmaceuticals by 29.6% in the first quarter. Creative Planning now owns 60,000 shares of the biotechnology company’s stock worth $156,000 after buying an additional 13,700 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $162,000. Rhumbline Advisers purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $184,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $292,000. 44.88% of the stock is owned by institutional investors and hedge funds.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.